Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
01 14Abilify
02 1Abilify Asimtufii
03 1Abilify LAI Franchise
04 16Abilify Maintena
05 1Abilify Maintena/Abilify Asimtufii
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 369
2019 Revenue in Millions : 319
Growth (%) : 16
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 369
2020 Revenue in Millions : 363
Growth (%) : 7
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 427
2021 Revenue in Millions : 369
Growth (%) : 16
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 459
2022 Revenue in Millions : 427
Growth (%) : 8
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : Neurology
Currency : USD
2024 Revenue in Millions : 486
2023 Revenue in Millions : 459
Growth (%) : 6
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : Neuroscience and Mental Health
Currency : USD
2015 Revenue in Millions : 31
2014 Revenue in Millions : 100
Growth (%) : 223%
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 226
2016 Revenue in Millions : 189
Growth (%) : 19
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 239
2017 Revenue in Millions : 200
Growth (%) : 20%
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 294
2018 Revenue in Millions : 239
Growth (%) : 23
